From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Clinical data
Trade namesWei Ni An
Other namesNylestriol; LY-49825; Ethinylestriol cyclopentyl ether; EE3CPE; 17α-Ethynylestriol 3-cyclopentyl ether
Routes of
By mouth
Drug classEstrogen; Estrogen ether
CAS Number
PubChem CID
Chemical and physical data
Molar mass380.528 g·mol−1
3D model (JSmol)

Nilestriol (INN) (brand name Wei Ni An; developmental code name LY-49825), also known as nylestriol (USAN, BAN), is a synthetic estrogen which was patented in 1971[1] and is marketed in China.[2][3] It is the 3-cyclopentyl ether of ethinylestriol, and is also known as ethinylestriol cyclopentyl ether (EE3CPE).[4] Nilestriol is a prodrug of ethinylestriol, and is a more potent estrogen in comparison.[4] It is described as a slowly-metabolized, long-acting estrogen and derivative of estriol.[5][6] Nilestriol was assessed in combination with levonorgestrel for the potential treatment of postmenopausal osteoporosis, but this formulation ultimately was not marketed.[7]

See also[edit]


  1. ^ Official Gazette of the United States Patent and Trademark Office: Patents. U.S. Department of Commerce, Patent and Trademark Office. 1975. p. 1677.
  2. ^ Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 891–. ISBN 978-1-4757-2085-3.
  3. ^ "Nilestriol".
  4. ^ a b McGuire W (14 December 2013). Experimental Biology. Springer Science & Business Media. pp. 161–. ISBN 978-1-4757-4673-0.
  5. ^ Schoenberg DR (1977). Biochemical Properties of the Cytoplasmic Estrogen Receptors from Immature Rat and Mature Rabbit Uteri (Ph.D. thesis). University of Wisconsin. p. A-17.
  6. ^ "Section 10: Obstetrics and gynecology". Excerpta Medica. 1978.
  7. ^ Aronson JK (21 February 2009). Meyler's Side Effects of Endocrine and Metabolic Drugs. Elsevier. pp. 173–. ISBN 978-0-08-093292-7.